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Novel EGFR-targeted strategy with 
hybrid peptide against oesophageal 
squamous cell carcinoma
Osamu Kikuchi1, Shinya Ohashi2, Tomohisa Horibe3, Masayuki Kohno3, Yukie Nakai2, 
Shin’ichi Miyamoto1, Tsutomu Chiba1, Manabu Muto2 & Koji Kawakami3
Epidermal growth factor receptor (EGFR) is a key molecule in the pathophysiology of oesophageal 
squamous cell carcinoma (OSCC). However, EGFR-targeted agents such as anti-EGFR antibody or 
tyrosine kinase inhibitors for OSCC have not demonstrated any clinical benefits. Recently, a novel 
chemotherapeutic agent, EGFR(2R)-lytic hybrid peptide, a composite of EGFR-binding peptide and lytic 
peptide fragments, has been shown to exhibit a potent anti-tumour effect against cancers that express 
high EGFR levels. In this study, we investigated the validity of employing EGFR(2R)-lytic hybrid peptide 
against OSCC cells both in vitro and in vivo. Additionally, the toxicity of this peptide was assessed in 
mice. We found high EGFR expression levels on the cell surface of OSCC cells, and the EGFR-binding 
peptide fragment showed high affinity for OSCC cells. A potent cytotoxic effect was induced within 
30 minutes by the exposure of OSCC cells to EGFR(2R)-lytic hybrid peptide. Furthermore, EGFR(2R)-lytic 
hybrid peptide markedly suppressed the tumour growth of OSCC cells in a xenograft model. Moreover, 
it did not cause any identifiable adverse effects in mice. Taken together, EGFR(2R)-lytic hybrid peptide 
was shown to be a valid therapeutic agent against OSCC, providing a crucial rationale regarding novel 
EGFR-targeted therapies against OSCC.
Oesophageal squamous cell carcinoma (OSCC) is a major histologic type of oesophageal cancer1, and the key 
therapy against advanced or metastatic OSCC is chemotherapy2–4. However, the therapeutic effect of anti-cancer 
agents that can be administered to treat OSCC is still limited. Indeed, combination chemotherapy with 
5-fluorouracil (5-FU) and a platinum-based drug for metastatic OSCC patients has been reported to lead to 
response rates of 30–40%5–7. In addition, docetaxel induced a partial response in only 20% of OSCC patients8.
Epidermal growth factor receptor (EGFR) is frequently (71–88%) expressed in OSCC tissues9, and its expres-
sion is associated with a poor outcome10. Several clinical trials of EGFR-targeted therapies, such as anti-EGFR 
antibodies and EGFR tyrosine kinase inhibitors (TKI), have been conducted for patients with advanced OSCC; 
however, the blockade of EGFR signalling has not been shown to sufficiently improve the outcome of those 
patients11–14. These data suggest that another strategy is required to facilitate the development of EGFR-targeted 
therapies against OSCC.
Recently, an EGFR-lytic hybrid peptide was developed as a new agent of EGFR-targeted therapy15. This 
peptide consists of two unique components: an EGFR-binding peptide fragment and a lytic peptide fragment 
(Fig. 1A). The EGFR-binding peptide fragment shows high-level affinity for human EGFR on the cell surface, 
whereas the lytic peptide fragment exhibits an amphipathic helical structure due to the presence of lysines (K) and 
leucines (L), and penetrates cellular membranes15. Thus, EGFR-lytic hybrid peptide could kill EGFR-expressing 
cells through the combined process of specific binding to EGFR on the cell surface and subsequently disintegrat-
ing cell membranes15.
A modified version of EGFR-lytic hybrid peptide has since been developed to improve its binding ability to 
EGFR by changing the second amino acid of the EGFR-binding sequence from histidine (H) to arginine (R)16, 
and this was designated EGFR(2R)-lytic hybrid peptide (Fig. 1B). The specific binding ability of EGFR(2R)-lytic 
hybrid peptide to recombinant EGFR was revealed by a binding assay and biophysical analysis using surface 
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plasmon resonance experiments16,17, and cytotoxic and anti-tumour effects of EGFR(2R)-lytic hybrid peptide 
were shown to be stronger than those of the original EGFR-lytic hybrid peptide16.
Based on these findings, we addressed the validity of EGFR(2R)-lytic hybrid peptide as a novel EGFR-targeted 
therapy against OSCC.
Results
EGFR expression and affinity of EGFR-binding peptide for surface of OSCC cells in vitro. Firstly, 
we examined the expression of EGFR in whole-cell lysates of OSCC cells by Western blotting. As shown in 
Fig. 2A, EGFR was highly expressed in all OSCC cells, while HEK293 cells, human embryonic kidney cells, 
showed low-level EGFR expression. Accordingly, we used HEK293 cells as negative control cells. Next, we inves-
tigated EGFR expression on the surface of OSCC cells by flow cytometry. As with the results of EGFR expression 
in whole-cell lysates, EGFR was expressed on the surface of all OSCC cells, but not HEK293 cells (Fig. 2B).
Then, we examined the affinity of EGFR-binding peptide for OSCC cells (TE-11R cells) and HEK293 cells. 
Although EGFR-binding peptide minimally bound to HEK293 cells, the affinity of EGFR-binding peptide for 
TE-11R cells was significantly increased in time- (Fig. 2C) and dose- (Fig. 2D) dependent manners.
Cytotoxicity of EGFR(2R)-lytic hybrid peptide against OSCC cells in vitro. Cytotoxic effects 
of EGFR(2R)-lytic hybrid peptide, the EGFR-binding peptide fragment, lytic peptide fragment, and the 
co-administration of EGFR-binding peptide and lytic peptide fragments on OSCC cells were investigated. As 
shown in Fig. 3, EGFR(2R)-lytic hybrid peptide showed a potent cytotoxicity against all OSCC cells, whereas 
the cytotoxic effects of the EGFR-binding peptide fragment, lytic peptide fragment, and co-administration of 
EGFR-binding peptide and lytic peptide fragments were limited. The IC50 values of EGFR(2R)-lytic hybrid pep-
tide for each OSCC cell are shown in Supplementary Table S1.
Rapid disintegration of OSCC cell membranes after exposure to EGFR(2R)-lytic hybrid pep-
tide in vitro. We examined the morphologic change of OSCC cells (TE-11R cells) after exposure to 
EGFR(2R)-lytic hybrid peptide. As shown in Fig. 4A, protrusion from cell membranes was observed within 
5 minutes after EGFR(2R)-lytic hybrid peptide exposure. Consistently, levels of extracellular LDH, a marker of 
cell membrane damage, were increased in the culture medium on exposure to EGFR(2R)-lytic hybrid peptide in 
a time-dependent manner (Fig. 4B).
Furthermore, to assess the real-time cytotoxicity in cells treated with this peptide, we conducted the ATP 
bioluminescence assay. Figure 4C shows that the ATP level was reduced to near zero within 30 minutes following 
exposure to EGFR(2R)-lytic hybrid peptide (Fig. 4C, Supplementary Fig. S1).
Anti-tumour effect of EGFR(2R)-lytic hybrid peptide against xenografted OSCC tumours. To 
investigate the anti-tumour effect of EGFR(2R)-lytic hybrid peptide against OSCC cells in vivo, xenografted 
tumours generated from TE-11R cells were treated with EGFR(2R)-lytic hybrid peptide. The EGFR(2R)-lytic 
hybrid peptide significantly suppressed the tumour growth of TE-11R cells (Fig. 5A) and induced tumour 
cell death (Fig. 5B), whereas the lytic peptide fragment without the EGFR-binding fragment did not show 
anti-tumour effects.
Figure 1. Scheme of peptides. (A) Original EGFR-lytic hybrid peptide consisting of an EGFR-binding peptide 
fragment and a lytic peptide fragment, with three glycine (G) spacers. (B) EGFR(2R)-lytic hybrid peptide 
consisting of a modified EGFR-binding peptide fragment, three glycine spacers, and a lytic peptide fragment. 
“(2R)” means that the second amino acid of the EGFR-binding peptide fragment is arginine (R, bold and 
underlined). Bold and italic letters are D-amino acids, whereas normal letters are L-amino acids. Sequences of 
EGFR-binding peptide and lytic peptide fragments are also shown.
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Figure 2. EGFR expression of OSCC cells and affinity of EGFR-binding peptide for OSCC cells. (A) EGFR 
expression levels in whole -cell lysates of HEK293 and OSCC cells (TE-5, TE-8, TE-10, TE-11, TE-5R, and 
TE-11R). The EGFR protein expression level was determined by Western blotting. β -Actin served as a loading 
control. EGFR protein was highly expressed in all OSCC cells, while its level was very low in HEK293 cells. 
(B) EGFR expressions on the cell surface of HEK293 and OSCC cells. Cells were stained with AlexaFluor 
647-conjugated monoclonal anti-EGFR antibody or IgG isotype control antibody. The Fluorescence intensity 
determined by flow cytometry showed that EGFR was expressed on the surface of OSCC cells, whereas HEK293 
cells minimally expressed it. (C,D) Affinity of EGFR-binding peptide for HEK293 and TE-11R cells. They were 
exposed to Fluorescein (FLC)-labelled EGFR-binding peptide, and the fluorescence intensity was assessed by 
flow cytometry. The Affinity of EGFR-binding peptide for cell membranes of TE-11R cells is increasing in time- 
(C) and dose- (D) dependent manners, but not in HEK293 cells. The assays were repeated three times, and data 
are shown as the mean ± SD. n.s.: not significant, *P < 0.05, **P < 0.01 vs. untreated (0 minutes) cells.
www.nature.com/scientificreports/
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Tolerability of EGFR(2R)-lytic hybrid peptide. We assessed the toxicity of EGFR(2R)-lytic hybrid pep-
tide in mice. Its administration led to no apparent gross abnormalities of the skin or abdominal cavities of mice. 
In addition, no histological damage was evident in organs (e.g., lung, kidney, oesophagus, and liver) (Fig. 6), 
which have been reported to express high levels of EGFR. Furthermore, neither significant haematological 
adverse effects nor weight loss was detected (Table 1, Supplementary Fig. S2).
Additionally, we tried to expose EGFR(2R)-lytic hybrid peptide on the stratified squamous epithelium. 
To this end, we conducted an organotypic 3D culture using human skin or oesophageal cells. Even though 
EGFR(2R)-lytic hybrid peptide was exposed to the stratified squamous epithelium, it did not cause any apparent 
histological damage (Fig. 7).
Figure 3. Cytotoxicity of EGFR(2R)-lytic hybrid peptide against OSCC cells in vitro. OSCC and control 
HEK293 cells were cultured with various concentrations (0–50 μM) of the EGFR-binding peptide fragment 
alone, lytic peptide fragment alone, co-administration of EGFR-binding peptide and lytic peptide fragments, or 
EGFR(2R)-lytic hybrid peptide for 30 minutes, and cell viability was measured with the WST-1 assay. A viability 
of 100% was defined as the amount of absorption at 450 nm found in control cells. Each point represents the 
mean ± S.D. (bars) from experiments conducted in sextuplicate, and the assays were repeated three times. 
Note that EGFR(2R)-lytic hybrid peptide exhibits a potent cytotoxicity against all OSCC cells at very low 
concentrations of less than 10 μM.
www.nature.com/scientificreports/
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Discussion
In the present study, we showed that all the OSCC cells we used expressed high levels of EGFR on their surface. 
The EGFR-binding fragment of EGFR(2R)-lytic hybrid peptide showed affinity for OSCC cells, but not HEK293 
Figure 4. Rapid disintegration of TE-11R cell membranes after exposure to EGFR(2R)-lytic hybrid 
peptide in vitro. (A) Phase-contrast images of TE-11R cells after exposure to EGFR(2R)-lytic hybrid peptide 
(10 μM). Extravasation from cell membranes (arrows) occurred at 5 minutes after exposure to EGFR(2R)-lytic 
hybrid peptide. Scale bar, 100 μm. (B) Extracellular LDH concentrations in culture medium after exposure 
to EGFR(2R)-lytic hybrid peptide. The relative LDH concentration (% of positive control with Triton X-100) 
was calculated. A time-dependent increase of extracellular LDH levels was found after exposure to EGFR(2R)-
lytic hybrid peptide (10 μM). Each point represents the mean ± S.D. (bars) from experiments conducted in 
sextuplicate. *P < 0.001 vs. untreated (0 minutes) cells. (C) The real-time cytotoxicity determined by ATP 
levels in TE-11R cells treated with EGFR(2R)-lytic hybrid peptide. TE-11R cells were transiently transfected 
with pGL4.50 vector and exposed with (right panel) or without (left panel) EGFR(2R)-lytic hybrid peptide 
(10 μM) for the indicated durations. Each point represents the mean ± S.D. (bars) from three cells. Note that 
rapid elimination of ATP was observed in the cells treated with EGFR(2R)-lytic hybrid peptide, but not in those 
treated without the peptide. These results indicate the rapid disintegration of the cell membrane and consequent 
cell death after exposure to EGFR(2R)-lytic hybrid peptide.
www.nature.com/scientificreports/
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cells. EGFR(2R)-lytic hybrid peptide showed a potent cytotoxicity as well as anti-tumour effect against OSCC 
cells both in vitro and in vivo. Furthermore, the administration of EGFR(2R)-lytic hybrid peptide did not cause 
any adverse haematological or histological effects in mice. We mainly used TE-11R cells to assess the cytotoxic 
or anti-tumour effect of EGFR(2R)-lytic hybrid peptide, because TE-11R cells are highly transformed cells with 
tumourigenicity18.
In this study, normal oesophageal keratinocytes were not used in our in vitro experiments. Normal oesopha-
geal keratinocytes are usually cultured in medium with a low calcium concentration (e.g., keratinocyte serum-free 
medium), in which these keratinocytes grow as undifferentiated basal cells19. Indeed, cultured normal oesopha-
geal keratinocytes express high levels of cytokeratin 14 (protein expressed in the basal layers of the oesophageal 
stratified epithelium) but low levels of cytokeratin 13 and involucrin (proteins expressed in the suprabasal lay-
ers of the oesophageal stratified epithelium)19. Thus, cultured normal oesophageal keratinocytes are cells that 
enrich basal cells, in which EGFR is expressed20. Accordingly, EGFR expression in cultured oesophageal kerati-
nocytes is high, and we could not show the difference between OSCC cells and normal oesophageal keratinocytes 
regarding the cytotoxicity with EGFR(2R)-lytic hybrid peptide in our in vitro experiments. Alternatively, the 
safety of EGFR(2R)-lytic hybrid peptide for the normal oesophagus was investigated by in vivo and organotypic 
3D-culture experiments.
We showed that EGFR(2R)-lytic hybrid peptide had a higher cytotoxicity than the lytic peptide fragment. 
According to the report of Papo et al. the lytic peptide fragment forms a random coil structure in a solution, in 
which its ability to cause cell membrane disruption is weak21. However, the form of lytic peptide can be changed 
to an α -helical structure when it is attracted to the cell surface by static electricity due to the lipid bilayer22,23 
and it exerts enhanced cytotoxicity with cell membrane disruption21. Notably, the EGFR expression level on the 
cell surface affects the cytotoxicity of EGFR-lytic hybrid peptide15, suggesting that the EGFR-binding peptide 
Figure 5. An anti-tumour effect of EGFR(2R)-lytic hybrid peptide against xenografted OSCC tumours.  
(A) Time-course volumes of xenografted tumours in vivo. TE-11R cells were allowed to grow for 5 weeks, and 
either PBS (○ ), lytic peptide (◇ : 4 mg/kg), or EGFR(2R)-lytic hybrid peptide (◾ : 4 mg/kg) was intravenously 
injected twice a week for a total of six doses, as indicated by the arrowheads (n = 5). The relative tumour 
volumes on day 28 in proportion to the volume on day 0 of the PBS, lytic peptide, and EGFR(2R)-lytic hybrid 
peptide groups were 11.0, 11.8 and 4.0, respectively. Each point represents the mean ± SEM (bars).*P < 0.05 vs. 
PBS-treated or lytic peptide-treated mice. (B) H&E staining of representative tumours in each group. Note that 
EGFR(2R)-lytic hybrid peptide induced potent tissue injury but not PBS or lytic peptide. Scale bar, 1 mm.
www.nature.com/scientificreports/
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fragment acts as an anchor to EGFR-expressing cells, and binding of the EGFR-binding fragment with EGFR 
on the cell surface contributes to change the lytic peptide fragment structurally and increase membranolytic 
cytotoxicity. Indeed, EGFR(2R)-lytic hybrid peptide showed high-level cytotoxicity against OSCC cells, whereas 
it was subtle when EGFR-binding peptide and lytic peptide fragments were not hybridized (co-administration 
of EGFR-binding peptide and lytic peptide fragments). These results indicate that the hybridisation of 
EGFR-binding peptide and lytic peptide fragments plays a key role to enhance the membranolytic cytotoxicity of 
lytic peptide fragments.
The therapeutic effect of existing EGFR-targeting therapy on ESCC is not sufficient. In OSCC, EGFR is fre-
quently expressed9, while the mutation rate is very low (1.1%)24. On the other hand, gene mutations and amplifi-
cations of EGFR downstream signalling pathways are frequently noted (78.6%)24. The therapeutic effect of existing 
Figure 6. Tolerability of EGFR(2R)-lytic hybrid peptide in mice. H&E staining of the lung, kidney, 
oesophagus, and liver of BALB/c mice after 6-times intravenous administration of EGFR(2R)-lytic hybrid 
peptide (4 mg/kg). Peptides were intravenously injected twice a week for a total of six doses. Note that the 
administration of EGFR(2R)-lytic hybrid peptide did not affect those organs. Scale bar, 200 μm.
EGFR(2R)-lytic Lytic PBS P
WBC (×103/μL) 2.5 ± 0.7 2.5 ± 0.2 3.1 ± 1.0 0.341
RBC (×104/μL) 1002.2 ± 62.1 909.4 ± 138.4 907.8 ± 216.3 0.550
Hb (g/dL) 16.1 ± 0.1 15.8 ± 0.7 15.3 ± 2.1 0.593
Hct (%) 52.9 ± 3.3 49.1 ± 7.4 47.6 ± 10.5 0.549
Plt (×104/μL) 81.5 ± 4.6 77.0 ± 11.6 69.8 ± 26.0 0.546
Table 1.  Haematological assessment after the administration of EGFR(2R)-lytic hybrid peptide to mice. 
EGFR(2R)-lytic hybrid peptide (4 mg/kg) was intravenously injected into BALB/c mice twice a week for a 
total of six doses. Blood samples were obtained one day after the final intravenous injection of EGFR(2R)-
lytic hybrid peptide. P-values were assessed by analysis of variance (ANOVA). Data are presented as the 
mean ± S.D. (n = 5). Note that EGFR(2R)-lytic hybrid peptide administration did not cause any haematological 
abnormalities in mice.
www.nature.com/scientificreports/
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EGFR-targeted therapies is achieved by blocking EGFR signalling in the tumour. Therefore, it is influenced by 
gene alteration of EGFR as well as EGFR downstream signal cascades. For example, in non-small lung cancer, 
response rates of EGFR-TKI are more favourable in patients with than without EGFR mutations25. Moreover, 
in colon cancer, the therapeutic effects of anti-EGFR antibody are weaker in patients with mutations of mole-
cules downstream of EGFR than those in patients without such mutations26,27. These results suggest that the low 
response rate to existing EGFR-targeted therapies in OSCC patients might be due to the low frequency of EGFR 
mutation as well as high frequency of gene alteration of EGFR downstream signalling pathways. In this study, the 
anti-tumour effect of EGFR(2R)-lytic hybrid peptide is considered to depend on cell membranous EGFR expres-
sion, but not on the intracellular EGFR signalling cascades, because the pretreatment of OSCC cells with Erlotinib 
did not affect the cytotoxicity of EGFR(2R)-lytic hybrid peptide (Supplementary Fig. S3). Taken together, we 
believe that EGFR-targeted therapy using EGFR(2R)-lytic hybrid peptide is a valid strategy against OSCC.
In this study, EGFR(2R)-lytic hybrid peptide induced rapid disintegration of the cell membrane and ATP 
depletion in OSCC cells. Cell membrane damage with LDH leakage indicates necrotic cell death28, whereas 
ATP depletion indicates the loss of functional integrity of living cells29. Although our data could not determine 
whether cell membrane disintegration precedes or follows ATP depletion, EGFR(2R)-lytic hybrid peptide could 
eliminate OSCC cells effectively in vitro.
EGFR(2R)-lytic hybrid peptide also showed a cytotoxic effect against 5-FU-resistant TE-5R and TE-11R cells, 
which were established by step-wise treatment with continuously increasing concentrations of 5-FU18,30. The 
mechanism of 5-FU resistance in TE-5R cells is based on a gene amplification of dihydropyrimidine dehydroge-
nase, a 5-FU-degrading enzyme30. On the other hand, the mechanisms of 5-FU resistance in TE-11R cells have 
not been fully elucidated; however, TE-11R cells show marked tumorigenicity18. In this study, we showed that 
EGFR expression on TE-5R and TE-11R cells was comparable with that on parental TE-5 and TE-11 cells. To our 
knowledge, there have been no reports regarding the relationship between 5-FU resistance and EGFR expression 
in OSCC. We suggest that EGFR(2R)-lytic hybrid peptide could be effective against OSCC cells irrespective of 
5-FU resistance as long as EGFR is overexpressed on their surface.
We suspect that EGFR(2R)-lytic hybrid peptide affects noncancerous cells that express EGFR (e.g., liver 
hepatocytes, respiratory epithelial cells of bronchus and lung, cells in kidney tubules, and epidermal kerat-
inocytes of oesophagus and skin31,32); however, it did not show marked toxicity against those normal tissues 
in mice. Although the EGFR-binding peptide sequence was originally determined by phage display screening 
using human recombinant EGFR17, it was further modified to improve the biomolecular interaction with human 
EGFR16. The homology of the extracellular domain of human and mouse EGFR is 89% (Supplementary Fig. S4), 
and the EGFR-binding peptide fragment could certainly bind to mouse cells (Supplementary Fig. S5).
A possible reason why EGFR(2R)-lytic hybrid peptide has more preferential cytotoxicity against cancer cells 
than noncancerous cells is suggested as follows: The lytic peptide fragment has a net positive charge21. On the 
other hand, cancer cells carry more negative charges due to the presence of negatively charged phosphatidylserine 
than noncancerous cells33. Accordingly, the lytic peptide fragment itself has more affinity toward cancerous than 
noncancerous cells21. Moreover, the EGFR-binding peptide fragment is considered to contribute to bind the lytic 
peptide fragment with high EGFR-expressing OSCC cells and help with the α -helical structural change of the 
lytic peptide fragment, as we described. Thus, the selectivity of EGFR(2R)-lytic hybrid peptide is suggested to be 
enhanced in OSCC cells.
Figure 7. Toxic effect of EGFR(2R)-lytic hybrid peptide against stratified squamous epithelium in 3D 
culture. EGFR(2R)-lytic hybrid peptide (1 mg/mL) or PBS was added to the apical site of 3D-culture cell 
sheets consisting of HPEK (human skin primary keratinocytes) or EPC2-hTERT (immortalized human 
oesophageal keratinocytes) for 30 minutes. Note that exposure to EGFR(2R)-lytic hybrid peptide did not 
adversely affect stratified squamous epithelium derived from human skin or oesophageal keratinocytes. H&E 
staining. Scale bar, 50 μm.
www.nature.com/scientificreports/
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As a limitation, the possibility that EGFR(2R)-lytic hybrid peptide might interact with other cell surface pro-
teins cannot be excluded. To conduct a first-in-human clinical trial, further examination regarding absorption, 
distribution, metabolism, and excretion as well as the metabolic stability of this peptide should be performed.
In conclusion, we conducted a preclinical study of using EGFR(2R)-lytic hybrid peptide against OSCC, and 
showed the validity of this peptide as a novel EGFR-targeted therapy.
Methods
Cell lines and cell culture. Human OSCC cell lines (TE-5, TE-8, TE-10, and TE-11) were obtained from 
Riken BioResource Center (Ibaragi, Japan)34. TE-5R and TE-11R cells, which are derived from TE-5 and TE-11 
cells, respectively, are 5-FU-resistant OSCC cells that were established via exposure to parental cells with gradually 
increasing concentrations of 5-FU18,30. All OSCC cells were cultured in RPMI1640 medium (Life Technologies 
Corp., Grand Island, NY, USA), supplemented with 10% foetal bovine serum (FBS; Life Technologies.), 100 μg/
mL of streptomycin, and 100 units/mL of penicillin (Life Tech.) at 37 °C in a 5% CO2 incubator.
HEK293, a cell line derived from human embryonic kidney cells35, served as low EGFR-expressing cells36,37. 
HEK293 was purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Japan) and cultured in DMEM medium 
(Life Tech.), supplemented with 10% FBS, 100 μg/mL of streptomycin, and 100 units/mL of penicillin at 37 °C in 
a 5% CO2 incubator.
Peptides. The following peptides were purchased from American Peptide Company Inc., (Sunnyvale, CA, 
USA) or Sigma-Aldrich Co., (St. Louis, MO, USA). Bold and italic letters are D-amino acids.
1. EGFR(2R)-lytic hybrid peptide: YRWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK (American Peptide)
2. EGFR-binding peptide: YRWYGYTPQNVI (Sigma-Aldrich)
3. Lytic peptide (without EGFR-binding sequence): KLLLKLLKKLLKLLKKK (American Peptide)
4. Fluorescein (FLC)-labelled EGFR-binding peptide: FLC-YRWYGYTPQNVI (labelled with FLC at its 
N-terminal, Sigma-Aldrich)
Measurement of EGFR expression. EGFR expression of the cells used in this study was measured by 
Western blotting and flow cytometry.
Whole-cell lysates were collected and Western blotting was performed as described previously18. Primary anti-
bodies and the titres used in this study were as follows: rabbit monoclonal anti-EGFR antibody (D38B1, #4267, 
Cell Signaling Technology, Inc., Danvers, MA, USA; 1:1,000), rabbit monoclonal anti-β -Actin antibody (13E5, 
#5125, Cell Signaling; 1:5,000). β -Actin served as loading controls for whole-cell lysates.
EGFR expression on the cell surface was detected with flow cytometry by measuring the fluorointensity of 
dye-conjugated anti-EGFR antibody which binds to cell-surface EGFR with a minor modification from a previous 
report38. In brief, cells were washed twice with PBS, and they were stained for 30 minutes on ice with AlexaFluor 
647-conjugated anti-EGFR or control antibodies in 2% FBS in PBS. Then, cells were washed twice with PBS and 
analysed with a flow cytometer (BD LSRFortessa Analyzer; BD Biosciences, San Jose, CA, USA). Antibodies 
and the titres were as follows: AlexaFluor 647-conjugated monoclonal anti-EGFR antibody (D38B1, #5588, Cell 
Signaling; 1:50), rabbit IgG isotype control (Alexa Fluor 647 Conjugate) antibody (#3452, Cell Signaling; 1:50). 
Collected data were analysed using FlowJo X software (Tree Star, Inc., Ashland, OR, USA).
Affinity of EGFR-binding peptide to cell surface EGFR. To determine the affinity of the EGFR-binding 
peptide fragment to the surface of OSCC cells, the FLC-labelled EGFR-binding peptide fragment was incubated 
with TE-11R cells and control HEK293 cells, and the fluorointensity was measured with a flow cytometer. In brief, 
these cells (1 × 106 cells/mL) were stained with the FLC-labelled EGFR-binding peptide fragment at the indicated 
times and/or concentrations on ice. After staining, these cells were washed twice with PBS, resuspended in 400 μL 
of ice-cold PBS, and the fluorointensity of FLC was detected through a 530/30 band-pass filter after excitation 
with a 488-nm blue laser.
WST-1 assays. The cytotoxic effect of the EGFR-binding peptide fragment alone, lytic peptide fragment 
alone, co-administration of EGFR-binding peptide fragment with lytic peptide fragment, or EGFR(2R)-lytic 
hybrid peptide on OSCC cells was determined by the WST-1 assay (Roche Applied Science, Upper Bavaria, 
Germany) following the manufacturer’s instructions. Cells (2 × 104 cells) were seeded in 96-well plates, and 
exposed to the indicated concentrations of peptides for 30 minutes. All data were obtained in sextuplicate with a 
multi-well plate reader as A450 – A630 (Infinite 200 pro, Tecan, Männedorf, Switzerland). Data are presented as the 
mean ± standard deviation (SD).
LDH cytotoxicity assay. LDH is a cytosolic enzyme and is released from cells when plasma membranes are 
damaged39. Therefore, we measured the extracellular LDH concentration with the LDH Cytotoxicity Detection 
Kit (Takara Bio, Otsu, Japan) to detect cell membrane damage induced by EGFR(2R)-lytic hybrid peptide. In brief, 
OSCC cells (2 × 104 cells) were plated in 96-well plates and, after 24-hour incubation, the media was changed to 
RPMI1640 (Life Tech.) without FBS, and they were exposed to the indicated concentrations of EGFR(2R)-lytic 
hybrid peptide in triplicate for 30 minutes. The media from each sample was transferred into a 96-well plate and 
incubated with a reaction mixture including tetrazolium salt, and the LDH concentration was measured as A492 
– A630 on a multi-well plate reader.
ATP real-time bioluminescence assay. ATP is the most important chemical energy reservoir in cells, 
and cell death results in a rapid ATP decrease29. ATP levels can be determined by assessing ATP bioluminescence 
www.nature.com/scientificreports/
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with the luciferin-luciferase reaction40. Therefore, this assay is used to assess real-time cell viability41. In this 
study, TE-11R cells were transiently transfected with firefly luciferase-containing reporter plasmids of the cyto-
megalovirus promoter (pGL4.50, Promega Corp., Madison, WI, USA) using Lipofectamine LTX (Life Tech.) 
according to the manufacturer’s protocol, and bioluminescence images were obtained with the LUMINOVIEW 
LV200 luminescence imaging system (40 × objective; 5-minute intervals; 10-second exposure; Olympus Corp., 
Tokyo, Japan) after incubation with or without EGFR(2R)-lytic hybrid peptide. The dish was kept at 37 °C in a 
humidified chamber and images were taken while observing promoter activity after the addition of D-luciferin 
(500 μM; Promega). The regions of interest (ROIs) were selected on each cell and the luminescence intensity was 
measured every five minutes using LV200. Data were analysed by AQUACOSMOS ver. 2.6 software (Hamamatsu 
Photonics, Shizuoka, Japan).
In vivo experiments. All experiments conformed to the relevant regulatory standards and were approved by 
the Institutional Animal Care and Use Committee of Kyoto University (Med Kyo 14523).
Xenograft transplantation was conducted as described previously18. Briefly, TE-11R cells (10 × 106) were sus-
pended in 50% matrigel (BD Biosciences), followed by their subcutaneous implantation into the dorsal skin of 
nude male mice (9 weeks of age; CLEA Japan, Inc., Tokyo, Japan). Xenografted tumours were used for the follow-
ing experiments and divided into 3 groups when they had reached a tumour volume of about 50–180 mm3 at 40 
days after injection. Tumours were free of evident necrosis at the beginning of injection. EGFR(2R)-lytic hybrid 
peptide (4 mg/kg), lytic peptide (4 mg/kg), or PBS was administered intravenously via the tail vein of mice twice 
a week for a total of six doses. The first administration day was defined as day 0. The tumours were monitored 
twice a week with a calliper, and the tumour volume (mm3) was calculated using the following formula: length x 
width2 × 0.5. The body weights were also monitored twice a week. The Relative tumour volume is shown as the 
Tumour volume on the indicated day/Tumour volume on day 0, and is presented as the mean ± standard error 
of the mean (SEM).
To assess the tolerability of EGFR(2R)-lytic hybrid peptide in vivo, we conducted a haematological and histo-
logical examination. We searched for anomalies in the abdominal cavity and assessed the appearance of the skin 
of mice, and then obtained blood and tissue samples (lung, heart, spleen, kidney, oesophagus, and liver) after 
6-times administration of EGFR(2R)-lytic hybrid peptide, lytic peptide, or PBS to BALB/c mice. The body weights 
were monitored twice a week. Blood samples were obtained under sedation 24 hours after the final intravenous 
injection of EGFR(2R)-lytic hybrid peptide. Then, mice were painlessly sacrificed under appropriate anaesthesia 
with the inhalation of isoflurane (Escain, Mylan Pharmaceuticals, Tokyo, Japan) and cervical dislocation, and 
tissue samples were collected in 10% formaldehyde phosphate buffer solution (Wako Pure Chemical Industries, 
Ltd.) for histopathology (n = 5).
Tolerability assessments with three-dimensional culture. To assess the safety of handling 
EGFR(2R)-lytic hybrid peptide in clinical situations such as preparing injection solution, we conducted an 
additional assessment using a three-dimensional (3D) culture model of human cells. 3D culture was established 
with the 3D Keratinocyte Starter Kit (3D-HPEK-50, CELLnTEC Advanced Cell Systems AG, Bern, Switzerland) 
following the manufacturer’s instructions. In brief, 2 × 105 human primary skin keratinocytes42 (HPEK, 
CELLnTEC) and human oesophageal keratinocytes immortalized with human telomerase reverse transcriptase 
(EPC2-hTERT)43 were seeded in the insert for 3 days with CnT-PCT medium (400 μL), and then the medium 
was changed to 3D Prime differentiation medium inside as well as outside the insert. After overnight culture 
with the 3D Prime differentiation medium, 3D cultures were initiated by aspirating all the medium from inside 
the insert and replacing only the outside medium with fresh 3D Prime differentiation medium up to the level 
of the membrane, to dry the surface within the inserts. After culture with the appropriate medium for 14 days, 
EGFR(2R)-lytic hybrid peptide (1 mg/mL, same concentration as used in mouse experiments) or PBS was added 
to the apical site of 3D-culture cell sheets, and cell sheets were harvested after exposure to EGFR(2R)-lytic hybrid 
peptide for 30 minutes. 3D cultures were fixed with 4% paraformaldehyde phosphate buffer solution (Wako Pure 
Chemical Industries, Ltd.) for histopathology (n = 3).
Statistical analyses. Data are presented as the mean ± standard deviation of the sextuplicate experiments, 
unless otherwise noted. Data were analysed using the 2-tailed Student’s t -test between two groups, or analysis of 
variance (ANOVA) between three groups. P < 0.05 was considered significant. All statistical analyses were per-
formed with SPSS 19 for Windows (SPSS Inc., Chicago, IL, USA).
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